[{"orgOrder":0,"company":"SpyBiotech","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spy Biotech and Serum Institute of India Announce Dosed First Subjects in \nPhase I\/II Trial of a Novel Virus-Like Particle Vaccine Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"3P Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Braavos Investment Advisers","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech Raises $32.5M in Series A Funding and Appoints Lutz B. Giebel as Chairman","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech And Oxford Collaborate On Epstein-Barr Virus Research And Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by SpyBiotech
The collaboration aims to support development of a vaccine against Epstein-Barr virus (EBV) by combining Oxford’s academic research capabilities with SpyBiotech’s proprietary SPYVLP platform.
SpyBiotech's primary program, SPYVLP01, a candidate vaccine, is presently undergoing Phase I clinical trial evaluation with patients for the treatment of human cytomegalovirus infection.
SPYVLP01, a vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology. There is currently no approved vaccine against HCMV.
The funding will support the development of next generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines using novel SpyVector platform. SpyVector is a platform based on recombinant adenovirus.
Proceeds will advance the clinical development of SpyBiotech’s novel vaccine technology platform, based on its proprietary SpyCatcher/SpyTag protein “superglue” technology.
SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.
SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. The Phase I/II study has been initiated in Australia.